Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 382, Issue 5–6, pp 511–524 | Cite as

Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts

  • M. Warnken
  • U. Reitzenstein
  • A. Sommer
  • M. Fuhrmann
  • P. Mayer
  • H. Enzmann
  • U. R. Juergens
  • K. Racké
ORIGINAL ARTICLE

Abstract

Insulin has been approved for inhaled application, but safety concerns remain, because of un-physiologically high insulin concentrations in the lung. Since insulin may act as growth factor, possible proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) on human lung fibroblasts were studied. As measure of proliferation [3H]-thymidine incorporation was studied in HEL-299, MRC-5, IMR-90 and primary human lung fibroblasts. In all cells, mRNA encoding IGF-1 receptors and two variants of insulin receptors was detected. Insulin and IGF-1 stimulated [3H]-thymidine incorporation in all cells. Comparison of the concentration-dependent effects in HEL-299 cells showed that IGF-1 and insulin glargine were more potent (EC50, 3 and 6 nM) and more effective (maximum increase, by 135–150%) than insulin and insulin detemir (EC50, 22 and 110 nM; maximum increase: by 80%). Proliferative effects of IGF-1 and insulin were inhibited to the same extent by an antibody (1H7) directed against the IGF-1 receptor α-subunit. Insulin-induced stimulation of [3H]-thymidine incorporation was reduced by 83% after siRNA-mediated down-regulation of IGF-1 receptor by about 75%, but not affected by a similar down-regulation of the insulin receptor. Insulin and IGF-1 caused rapid up-regulation of the early genes FOS, EGR-1 and EGR-2 as well as of the gene coding for IGF-1. In conclusion, in human lung fibroblasts insulin exerts marked proliferative effects and the pharmacological profile of this response as well as specific receptor knock-down experiments suggest mediation via IGF-1 receptors. The risk of unwanted structural lung alterations by long-term inhalative application of insulin should be considered.

Keywords

Insulin Insulin-like growth factor-1 (IGF-1) Lung fibroblasts Airway remodelling 

Notes

Acknowledgement

This work was supported by the Federal Institute for Drugs and Medical Devices (V-9908/68602/2007). The paper contains part of the Ph.D. thesis of UR. We thank Sabine Mering for excellent technical assistance.

References

  1. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586–623PubMedCrossRefGoogle Scholar
  2. Ceglia L, Lau J, Pittas AG (2006) Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 145:665–675PubMedGoogle Scholar
  3. Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50:2534–2543PubMedCrossRefGoogle Scholar
  4. Freitag A, Reimann A, Wessler I, Racké K (1996) Effects of bacterial lipopolysaccharides (LPS) and tumor necrosis factor-α (TNF-α) on rat tracheal epithelial cells in culture: morphology, proliferation and induction of NO synthase. Pulm Pharmacol 9:149–156PubMedCrossRefGoogle Scholar
  5. Gosens R, Nelemans SA, Hiemstra M, Grootte Bromhaar MM, Meurs H, Zaagsma J (2003) Insulin induces a hypercontractile airway smooth muscle phenotype. Eur J Pharmacol 481:125–131PubMedCrossRefGoogle Scholar
  6. Haag S, Warnken M, Juergens UR, Racké K (2008) Role of Epac1 in mediating anti-proliferative effects of prostanoid EP2 receptors and cAMP in human lung fibroblasts. Naunyn-Schmiedeberg’s Arch Pharmacol 378:617–630CrossRefGoogle Scholar
  7. Hunt LM, Valenzuela MA, Pugh JA (1997) NIDDM patients’ fears and hopes about insulin therapy. The basis of patient reluctance. Diab Care 20:292–298CrossRefGoogle Scholar
  8. Johnson DW, Saunders HJ, Baxter RC, Field MJ, Pollock CA (1998) Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int 54:747–757PubMedCrossRefGoogle Scholar
  9. Kosaki A, Nelson J, Webster NJ (1998) Identification of intron and exon sequences involved in alternative splicing of insulin receptor pre-mRNA. J Biol Chem 273:10331–10337PubMedCrossRefGoogle Scholar
  10. Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C, Trüb T (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMedCrossRefGoogle Scholar
  11. Lenzer J (2006) Inhaled insulin is approved in Europe and United States. BMJ 332:321PubMedCrossRefGoogle Scholar
  12. Li SL, Kato J, Paz IB, Kasuya J, Fujita-Yamaguchi Y (1993) Two new monoclonal antibodies against the alpha subunit of the human insulin-like growth factor-I receptor. Biochem Biophys Res Commun 196:92–98PubMedCrossRefGoogle Scholar
  13. Lindemann D, Racké K (2003) Glucocorticoid inhibition of interleukin-4 (IL-4) and interleukin-13 (IL-13) induced up-regulation of arginase in rat airway fibroblasts. Naunyn-Schmiedeberg’s Arch Pharmacol 368:546–550CrossRefGoogle Scholar
  14. Ludwig CU, Menke A, Adler G, Lutz MP (1999) Fibroblasts stimulate acinar cell proliferation through IGF-I during regeneration from acute pancreatitis. Am J Physiol 276:G193–G198PubMedGoogle Scholar
  15. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blättler WA, Chittenden T, Singh R (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 63:5073–5083PubMedGoogle Scholar
  16. Matthiesen S, Bahulayan A, Kempkens S, Fuhrmann R, Stichnote C, Haag S, Juergens UR, Racké K (2006) Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 35:621–627PubMedCrossRefGoogle Scholar
  17. Mayer P, Ammon S, Braun H, Tischmeyer H, Riechert U, Kahl E, Höllt V (2002) Gene expression profile after intense second messenger activation in cortical primary neurons. J Neurochem 82:1077–1086PubMedCrossRefGoogle Scholar
  18. McMahon GT, Arky Ronald A (2007) Inhaled insulin for diabetes mellitus. N Engl J Med 356:497–502PubMedCrossRefGoogle Scholar
  19. Párrizas M, Gazit A, Levitzki A, Wertheimer E, LeRoith D (1997) Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138:1427–1433PubMedCrossRefGoogle Scholar
  20. Racke K, Haag S, Bahulayan A, Warnken M (2008) Pulmonary fibroblasts, an emerging target for anti-obstructive drugs. Naunyn-Schmiedeberg’s Arch Pharmacol 378:193–201CrossRefGoogle Scholar
  21. Reitzenstein U, Fuhrmann M, Mayer P, Enzmann H, Racké K, Warnken M (2009) Characterization of proliferative effects of insulin in human lung fibroblasts. Naunyn-Schmiedeberg’s Arch Pharmacol 379:Suppl 1–Suppl 10Google Scholar
  22. Saygun I, Karacay S, Serdar M, Ural AU, Sencimen M, Kurtis B (2008) Effects of laser irradiation on the release of basic fibroblast growth factor (bFGF), insulin like growth factor-1 (IGF-1), and receptor of IGF-1 (IGFBP3) from gingival fibroblasts. Lasers Med Sci 23:211–215PubMedCrossRefGoogle Scholar
  23. Seino S, Bell GI (1989) Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 159:312–316PubMedCrossRefGoogle Scholar
  24. Siekmeier R, Scheuch G (2008) Inhaled insulin—does it become reality? J Physiol Pharmacol 59(Suppl 6):81–113PubMedGoogle Scholar
  25. Yoshimoto H, Ishihara H, Ohtsuru A, Akino K, Murakami R, Kuroda H, Namba H, Ito M, Fujii T, Yamashita S (1999) Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol 154:883–889PubMedGoogle Scholar
  26. Zambanini A, Newson RB, Maisey M, Feher MD (1999) Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 46:239–246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • M. Warnken
    • 1
  • U. Reitzenstein
    • 1
  • A. Sommer
    • 1
  • M. Fuhrmann
    • 1
  • P. Mayer
    • 3
  • H. Enzmann
    • 3
  • U. R. Juergens
    • 2
  • K. Racké
    • 1
  1. 1.Institute of Pharmacology and ToxicologyUniversity of BonnBonnGermany
  2. 2.Department of Pulmonary DiseasesUniversity Hospital Bonn, Clinic and Policlinic IIBonnGermany
  3. 3.Federal Institute for Drugs and Medical DevicesBonnGermany

Personalised recommendations